Who
Stuart A. Kingsley
Director
Company insider
Files Form 4 as: Director, Indivior Pharmaceuticals; President and CEO, Scholar Rock Holding; Director, Protara Therapeutics; President and COO, Medicines Co /de; EVP, Global Comm. Operations, Biogen; SVP, GYN Surgical, Hologic; President, Diagnostics Div., Cytyc.
In numbers
- Trades disclosed
- 90
- Buys
- 1
- Sells
- 5
- Bought
- $60K
- Sold
- $16.0M
- Companies
- 7
- Companies where not an officer
- 2
- First trade
- 26 Jul 2006
- Last trade
- 13 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 14 May 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,518 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,518 at $0.00 | filing |
| 6 Mar 2026filed 11 Mar 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $30K940 at $31.87 | filing |
| 6 Mar 2026filed 11 Mar 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $30K940 at $31.87 | filing |
| 26 Jan 2026filed 28 Jan 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,722 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,722 at $0.00 | filing |
| 1 Feb 2021filed 3 Feb 2021 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 1 Feb 2021filed 3 Feb 2021 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 16 Jul 2020filed 17 Jul 2020 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —429,684 at $0.00 | filing |
| 20 May 2020filed 21 May 2020 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,316 at $0.00 | filing |
| 8 Jun 2018filed 11 Jun 2018 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,700 at $0.00 | filing |
| 20 Jun 2017filed 21 Jun 2017 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,666 at $0.00 | filing |
| 1 Mar 2017filed 2 Mar 2017 | Medicines Co /de | SEC FORM 4 Code A | —11,386 at $0.00 | filing |
| 1 Mar 2017filed 2 Mar 2017 | Medicines Co /deoption or derivative | SEC FORM 4 Code A | —70,265 at $0.00 | filing |
| 9 Jun 2016filed 14 Jun 2016 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,666 at $0.00 | filing |
| 16 May 2016filed 18 May 2016 | Medicines Co /deoption or derivative | SEC FORM 4 Code A | —398,232 at $0.00 | filing |
| 16 Oct 2015filed 19 Oct 2015 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,333 at $0.00 | filing |
| 23 Feb 2015filed 25 Feb 2015 | BIIB Biogenoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,220 at $0.00 | filing |
| 12 Feb 2015filed 17 Feb 2015 | BIIB BiogenBiotechnology | SEC FORM 4 Code M | —2,246 at $0.00 | filing |
| 12 Feb 2015filed 17 Feb 2015 | BIIB BiogenBiotechnology | SEC FORM 4 Code F | $415K1,058 at $392.11 | filing |
News
Contrasting Orion OYJ (OTCMKTS:ORINY) & Indivior (NASDAQ:INDV)INDV · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Stuart A. Kingsley; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.